Bard PowerPort claims: who can file and what to do

Who may qualify?

If you had a Bard port and a serious problem after it was placed, ask a lawyer about a claim. The federal cases include claims that implanted ports caused harm. A problem after treatment does not itself prove a defect. [1]

Start with the device name in the hospital record. Keep the implant card, if you have it, and ask for the report from the placement procedure. The dated court order discusses a PowerPort with a silicone tube and an alleged infection. It does not say that every claim must involve a broken tube or the same material. [1]

Write down the problem your doctor diagnosed and when it began. Add the dates of hospital visits, scans, treatment and any port removal. Separate what the doctor found from what you think may have happened. Ask the lawyer which records and legal rules matter. This guide does not set a firm’s model list, injury screen or minimum time of use.

What could I get?

No one has announced a personal payment in the September 25 order reviewed here. The ruling keeps disputed claims in one case alive; it does not price your claim. Ask a lawyer to assess the proof and any actual offer. [1]

A civil lawsuit may ask for money for harm. Asking is different from receiving an award, and the person making the claim must support it with evidence. Keep bills, care records and notes about work you missed. Ask which losses the law for your claim allows, rather than adding them to a payout calculator. [7]

If someone offers money, ask for the full terms and the deductions that would apply. A private agreement and a court award can involve different steps. Neither a device name nor a result for another patient gives you a personal amount. This guide does not verify a later payment program, private offer or date when money would arrive. [7] [10]

Is there a deadline?

Ask a lawyer to check the time limit for your own port claim. It depends on the claim, the law and the relevant facts. A court’s date for one patient is not a filing date for everyone else. [9] [1]

Bring the implant date, the first symptoms, the diagnosis and anything you were told about a device problem. Include where you lived and any earlier lawsuit or agreement. Ask which dates matter and why. Do not assume the clock starts when you saw a recall, an ad or this page. This guide does not calculate a personal deadline. [9]

The September order considered a deadline dispute under Florida law using that patient’s evidence. It did not create a single nationwide time limit. An old implant date is a reason to ask for review, rather than guessing that a claim is open or closed. Give the lawyer the actual history before relying on an online rule of thumb. [1] [9]

What happens after I check?

Prepare the device and care history, ask who will assess the claim, and read any terms before hiring a firm. These are steps to discuss with the receiving lawyer. A website inquiry alone does not file a lawsuit. [7]

First, list the exact port, procedure dates and medical findings. Mark a date as uncertain if you do not know it. Next, ask the firm which injury and legal route it is reviewing. Then ask what it needs from you and whether it can offer representation. Do not read a request for more records as a promise that the case has been accepted.

Before sharing files, check who receives them and how the firm will use them. Ask about contact consent, fees and how to keep a copy of the agreement. If you already have a lawyer for this problem, discuss the next step with that lawyer first. A court record does not establish a website’s privacy terms, response time or service price.

Questions people ask

These questions focus on port records, the federal cases and the limits of a recall. They offer practical questions for the care team and lawyer. They do not decide your diagnosis, legal deadline or the result of a claim.

How Bard PowerPort Catheters Cause Harm

Bard PowerPort implanted port catheters, widely used to deliver chemotherapy and other intravenous therapies, have been linked to serious injuries resulting from catheter fracture, migration, and failure. The devices use Chronoflex polyurethane — a material documented to degrade over time inside the body — placing patients at risk of life-threatening complications.

Catheter Fracture from Polyurethane Degradation

Bard's PowerPort catheters are manufactured with Chronoflex AL polyurethane, a material susceptible to environmental stress cracking and oxidative degradation when exposed to bodily fluids over time. As the polymer weakens, micro-cracks form and propagate, eventually causing the catheter to fracture. Fragmented catheter pieces can then travel freely through the bloodstream.

Tip Embolism to the Heart and Lungs

When a fractured catheter segment enters the vascular system, it becomes an embolus — a foreign body migrating through the venous circulation. These fragments frequently lodge in the right side of the heart or pulmonary arteries, causing cardiac arrhythmia, pulmonary embolism, perforation, or cardiac tamponade. Retrieval often requires emergency interventional radiology or open-heart surgery.

Port Body Mechanical Failure

The titanium port reservoir and its connection to the catheter can fail due to design deficiencies, manufacturing defects, or improper seating of the catheter hub. Separation at the port-catheter junction allows infused medications to extravasate into surrounding tissue rather than entering the bloodstream, potentially causing severe chemical burns and necrosis in the chest wall.

Catheter-Associated Thrombosis

The catheter's surface and its positioning in the superior vena cava can trigger the body's clotting cascade, leading to catheter-associated deep vein thrombosis (DVT). Thrombi can partially or fully occlude the catheter lumen, render the port non-functional, and — if they dislodge — travel to the lungs and cause pulmonary embolism. Cancer patients on chemotherapy face elevated baseline clotting risk, compounding the danger.

Catheter-Related Bloodstream Infection (CRBSI)

Implanted ports provide a direct pathway for bacteria to enter the bloodstream. When the catheter material degrades or the port septum is accessed repeatedly, biofilm formation on the catheter surface can seed systemic infection. Catheter-related bloodstream infections (CRBSIs) can progress to sepsis and septic shock, conditions that are particularly dangerous for immunocompromised oncology patients.

• Long-Term Implantation in Vulnerable Patients: PowerPort devices are most commonly implanted in cancer patients who require reliable venous access for extended chemotherapy regimens. These patients are simultaneously immunocompromised, hypercoagulable due to malignancy, and less able to tolerate the additional physiological stress of device failure, creating a uniquely high-risk population.
• Chronoflex Polyurethane Material Deficiency: Independent research and MDL expert testimony have documented that Chronoflex AL, the polyurethane used in Bard catheters, is prone to degradation under the oxidative and enzymatic conditions present in the human body. Competing devices use silicone or alternative polymers with superior in-vivo stability, suggesting that the choice of Chronoflex was a preventable design deficiency.
• Delayed Fracture Detection: Catheter fractures often occur without immediate symptoms. Patients and clinicians may be unaware of a fracture until the migrated fragment causes acute cardiac or pulmonary symptoms. By the time injury is detected, the catheter fragment may be deeply embedded in cardiac tissue, making retrieval highly complex and dangerous.
• Inadequate Warning and Training: Plaintiffs in MDL 3081 allege that Bard failed to adequately warn physicians and patients about the elevated fracture risk associated with Chronoflex catheters and did not provide sufficient guidance on radiographic surveillance protocols that might enable earlier detection of catheter degradation.
• Polyurethane catheters have well-documented material degradation risks compared to silicone alternatives, supported by peer-reviewed literature.
• FDA MAUDE data reflects thousands of adverse event reports involving Bard port catheter fracture and migration.
• MDL 3081 (D. Arizona) groups the federal cases for pretrial work; consolidation is a case-management step and does not decide whether the device is defective.
• Emergency retrieval procedures for migrated catheter fragments carry their own serious procedural risks, compounding patient harm.

The harm mechanism in Bard PowerPort litigation is fundamentally a product defect claim: a material chosen for catheter construction that predictably degrades inside the body, combined with alleged failure to warn patients and clinicians of this known risk. Establishing the catheter fracture-to-injury chain is central to plaintiff causation cases.

Sepsis and Infection from Catheter Fragments

A fractured catheter fragment acts as a persistent intravascular foreign body that bacteria readily colonize, forming a protective biofilm on the fragment surface. This biofilm continuously sheds bacteria into the bloodstream, causing catheter-related bloodstream infection (CRBSI), bacteremia, sepsis, and in severe cases, infective endocarditis — bacterial infection of the heart valves. Because the fragment is often in close proximity to the tricuspid or pulmonary valve, vegetation can form on valve leaflets, leading to valve destruction and the need for surgical valve repair or replacement. Gram-positive organisms, particularly Staphylococcus aureus and coagulase-negative staphylococci, are the most common pathogens isolated in catheter-fragment-associated infections. Sepsis caused by endovascular foreign bodies is notoriously difficult to eradicate with antibiotics alone — definitive treatment requires removal of the infected fragment. Patients who are immunocompromised from cancer chemotherapy face dramatically elevated risk of septic morbidity and mortality.

• High fever, chills, and rigors (classic signs of bacteremia)
• Persistent positive blood cultures despite antibiotic treatment
• New heart murmur or echocardiographic evidence of valve vegetation
• Septic emboli to skin, joints, kidneys, or brain
• ICU admission for hemodynamic instability from septic shock
• Multi-organ failure in setting of uncontrolled infection
• Immunocompromised state from cancer chemotherapy
• Diabetes mellitus (impairs immune response to infection)
• Prolonged catheter implantation without surveillance imaging
• Recurrent bacteremia without identifiable source
• Prior catheter-related infection history
• Delay in recognizing fractured catheter as source of infection
• Blood culture series and echocardiography (TTE and TEE) for diagnosis
• 6 weeks of IV antibiotics for infective endocarditis (per AHA guidelines)
• Surgical cardiac valve repair or replacement for refractory endocarditis
• Fragment retrieval as essential component of infection source control
• Long-term infectious disease follow-up and monitoring for relapse

C.R. Bard and Becton Dickinson: Corporate Accountability

C.R. Bard, Inc. manufactured and marketed the PowerPort implanted port catheter for decades. The acquisition means BD now faces the full financial and reputational exposure from thousands of MDL 3081 plaintiffs alleging serious injuries caused by Bard's allegedly defective catheter design.

Corporate Knowledge and Delayed Action

Internal documents produced in MDL 3081 discovery and cited by plaintiff experts allege that C.R. Bard possessed knowledge of Chronoflex polyurethane degradation risks and catheter fracture reports for years before taking meaningful corrective action. Plaintiffs argue that Bard prioritized market share over patient safety and that Becton Dickinson, upon acquiring Bard, inherited both the defective product and the corporate culture that produced it.

• MDL plaintiffs allege internal Bard testing showed catheter degradation risks that were not reflected in physician warnings or product labeling.
• FDA MAUDE reports submitted by Bard itself acknowledged catheter fracture events, yet design changes were not implemented in a timely manner.
• Becton Dickinson has faced shareholder scrutiny over its failure to disclose the full scope of PowerPort litigation liability at the time of the Bard acquisition.
• Plaintiff attorneys have sought documents relating to Bard's marketing of PowerPort to oncology centers, alleging that sales incentives suppressed safety communications.

Becton Dickinson, as the corporate successor to C.R. Bard, bears full financial responsibility for PowerPort litigation. On September 25, 2026, Judge David G. Campbell let one MDL 3081 case (Lattanzio) proceed past summary judgment; that ruling is about one case, not a verdict or a payment. No settlement has been announced. What any claim is worth depends on its facts, and no one can promise an amount.

Bard PowerPort Lawsuit Filing Deadlines

The statute of limitations for Bard PowerPort catheter injury claims is typically 2 to 4 years, but the applicable deadline varies by state and is shaped critically by the discovery rule — which starts the clock not at implantation, but at the time the patient discovered, or reasonably should have discovered, that the catheter had fractured and caused injury.

The Discovery Rule Is Critical in PowerPort Cases

Unlike car accident claims where the injury and its cause are immediately apparent, many Bard PowerPort patients do not learn that their catheter fractured until months or years after the fracture occurred. The catheter fractures silently — without pain or sensation at the moment of fracture — and the resulting fragment may travel to the heart or lungs before causing symptoms. Symptoms such as chest pain, shortness of breath, or recurrent bloodstream infections may be initially attributed to the patient's underlying medical condition (such as cancer) rather than to a device defect. The discovery rule tolls (pauses) the statute of limitations until the plaintiff knew or reasonably should have known that: (1) the catheter had fractured; (2) the fracture was a product of the device rather than a natural occurrence; and (3) the fracture caused cognizable harm. This means that patients who received a PowerPort years ago may still have a viable claim if they recently discovered the catheter-related injury. In states with specific statutes of repose for medical device claims — typically 10 to 12 years from the date of device implantation — the repose period may cap the ultimate filing window even where the discovery rule would otherwise allow later filing.

A California patient received a PowerPort in 2018 for chemotherapy. In early 2025, routine chest X-ray reveals a fractured catheter fragment in the right ventricle. She had no prior symptoms attributed to the device.

California has a 2-year statute of limitations for personal injury claims (CCP § 335.1), running from the date of discovery. Her clock began in early 2025 when imaging revealed the fragment. She has until early 2027 to file suit. Joining the MDL in Arizona does not require refiling in California — her claim can be transferred after filing in any federal court.

A Texas patient had a PowerPort placed in 2016. He developed recurrent bacteremia in 2021 and was told by his cardiologist in 2022 that the infections were likely linked to a fractured catheter segment visible on echo.

Texas has a 2-year SOL for medical device product liability claims (CPRC § 16.003). Under the discovery rule, the clock arguably began in 2022 when the causal link was identified. If he files in 2024, a court would need to decide whether he should have discovered the connection sooner. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

Do not assume you missed your deadline because your PowerPort was implanted years ago. The discovery rule may preserve your claim if you recently learned of the catheter fracture. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.